Focus Partners Wealth
ACAD icon

Focus Partners Wealth’s Acadia Pharmaceuticals ACAD Stock Holding History

Focus Partners Wealth’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
9,406
-1,248
-12% -$29.8K ﹤0.01% 2398
2025
Q4 		$285K Sell
10,654
-9,219
-46% -$220K ﹤0.01% 2253
2025
Q3 		$2.11M Buy
+19,873
New +$470K ﹤0.01% 997

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Focus Partners Wealth's ACAD Position: Q1 2026 in Review

Focus Partners Wealth reduced its Acadia Pharmaceuticals (ACAD) stake by 12% in Q1 2026, selling an estimated $29.8K and leaving 9,406 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

Focus Partners Wealth first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.11M in Q3 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Focus Partners Wealth held 9,406 shares of Acadia Pharmaceuticals worth $209K as of Q1 2026.
  • Focus Partners Wealth sold 1,248 Acadia Pharmaceuticals shares in Q1 2026, an estimated $29.8K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2398 holding.
  • Focus Partners Wealth first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Focus Partners Wealth's Acadia Pharmaceuticals position peaked at $2.11M in Q3 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.